Metraipolis › archive › dc_1641afcf84fd
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors — Europe PMC PMID:41759225
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41759225
- DOI
- 10.1016/j.esmoop.2026.106076
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-07T17:34:52.484Z
- SHA-256 of the archived text
1b43577e0a641ac0a273fe1609b5b72a792d97ed596322a96ac5f1052fde1435- Stable URL of this page
https://metraipolis.com/documento/dc_1641afcf84fd
How to cite
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors — Europe PMC PMID:41759225 — Europe PMC (en), https://europepmc.org/article/MED/41759225 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1641afcf84fd (Metraipolis archive dc_1641afcf84fd, sha256 1b43577e0a641ac0a273fe1609b5b72a792d97ed596322a96ac5f1052fde1435)
BibTeX
@misc{dc1641afcf84fd,
title = {ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors — Europe PMC PMID:41759225},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41759225},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1641afcf84fd; sha256 1b43577e0a641ac0a273fe1609b5b72a792d97ed596322a96ac5f1052fde1435},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41759225. Agents can read the archived copy with the MCP tool read_document.